Table 1.
Clinicopathological characteristics of the studied MIS-C patients.
| Characteristics | MIS-C cohorts |
||
|---|---|---|---|
| Discovery cohort (N = 29) | Validation cohort (N = 14) | Entire cohort (N = 43) | |
| Gender - Frequency (%) | |||
| Female | 9 (31.0%) | 8 (57.1%) | 17 (39.5%) |
| Male | 20 (69.0%) | 6 (42.9%) | 26 (60.5%) |
| Age (years) - Median [range] | 8.0 [0.5–17] | 6.5 [1–11] | 7.0 [0.5–17] |
| Age group- Frequency (%) | |||
| ≤2 yr | 5 (17.2%) | 1 (7.1%) | 6 (14.0%) |
| 3–5 yr | 4 (13.8%) | 5 (35.7%) | 9 (20.9%) |
| 6–9 yr | 7 (24.1%) | 5 (35.7%) | 12 (27.9%) |
| 10–13 yr | 8 (27.6%) | 3 (21.4%) | 11 (25.6%) |
| 14–18 yr | 5 (17.2%) | 0 (0.0%) | 5 (11.6%) |
| Ethnicity - Frequency (%) | |||
| West-Eurasia | 20 (69.0%) | 11 (78.6%) | 31 (72.1%) |
| Central-South America | 6 (20.7%) | 2 (14.3%) | 8 (18.6%) |
| African | 3 (10.3%) | 1 (7.1%) | 4 (9.3%) |
| Underlying conditions - Frequency (%) | |||
| Previously healthy | 26 (89.7%) | 14 (100%) | 40 (93.0%) |
| Asthma | 3 (10.3%) | 0 (0%) | 3 (7.0%) |
| SARS-CoV-2 status- Frequency (%) | |||
| IgG and/or PCR positive | 26 (89.7%) | 13 (92.9%) | 39 (90.7%) |
| Near contact with SARS-CoV-2 positive* | 3 (10.3%) | 1 (7.1%) | 4 (9.3%) |
| Detection of additional virus - Frequency (%)† | 5 (17.2%) | 0 (0.0%) | 5 (11.6%) |
| Organ system involvement - Frequency (%) | |||
| Two systems | 4 (13.8%) | 2 (14.3%) | 6 (14.0%) |
| Three systems | 5 (17.2%) | 6 (42.9%) | 11 (25.6%) |
| Four or more systems | 20 (69.0%) | 6 (42.9%) | 26 (60.5%) |
| Gastrointestinal involvement# - Frequency (%) | 26 (89.7%) | 11 (78.6%) | 37 (86.0%) |
| Respiratory involvement# - Frequency (%) | 21 (72.4%) | 6 (42.9%) | 27 (62.8%) |
| Cardiovascular involvement# - Frequency (%) | 22 (75.9%) | 11 (78.6%) | 33 (76.7%) |
| Mucocutaneous involvement# - Frequency (%) | 19 (65.5%) | 10 (71.4%) | 29 (67.4%) |
| Hematologic involvement# - Frequency (%) | 21 (72.4%) | 8 (57.1%) | 29 (67.4%) |
| Neurologic involvement# - Frequency (%) | 6 (20.7%) | 2 (14.3%) | 8 (18.6%) |
| Renal involvement# - Frequency (%) | 3 (10.3%) | 0 (0.0%) | 3 (7.0%) |
| Musculoskeletal involvement# - Frequency (%) | 1 (3.4%) | 1 (7.1%) | 2 (4.7%) |
| Highest level of care - Frequency (%) | |||
| Home | 1 (3.4%) | 0 (0.0%) | 1 (2.3%) |
| Ward | 8 (27.6%) | 9 (64.3%) | 17 (39.5%) |
| Intensive care unit | 20 (69.0%) | 5 (35.7%) | 25 (58.1%) |
| Oxygen supplementation - Frequency (%) | |||
| None | 9 (31.0%) | 10 (71.4%) | 19 (44.2%) |
| Nasal cannula | 7 (24.1%) | 1 (7.1%) | 8 (18.6%) |
| Non-Invasive Ventilation or High Flow Oxygen | 10 (34.5%) | 2 (14.3%) | 12 (27.9%) |
| Mechanical Ventilation | 2 (6.9%) | 1 (7.1%) | 3 (7.0%) |
| Extracorporeal membrane oxygenation | 1 (3.4%) | 0 (0%) | 1 (2.3%) |
⁎
For cases of unknown SARS-CoV-2 status.
†
Additional viruses: Parainfluenza virus type 4 (HPIV-4), Rhinovirus/Enterovirus (HRV/ENT) and Adenovirus.
#
Following the definitions used for organ involvement in Feldstein et al., N Engl J Med, 2020.